{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T04:08:49Z","timestamp":1785298129561,"version":"3.55.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T00:00:00Z","timestamp":1620864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T00:00:00Z","timestamp":1620864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003009","name":"Science and Technology Development Fund","doi-asserted-by":"publisher","award":["5480"],"award-info":[{"award-number":["5480"]}],"id":[{"id":"10.13039\/501100003009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012632","name":"Nazarbayev University","doi-asserted-by":"publisher","award":["110119FD4516"],"award-info":[{"award-number":["110119FD4516"]}],"id":[{"id":"10.13039\/501100012632","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R03DA052179"],"award-info":[{"award-number":["R03DA052179"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>As the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) pandemic engulfs millions worldwide, the quest for vaccines or drugs against the virus continues. The helicase protein of SARS-CoV-2 represents an attractive target for drug discovery since inhibition of helicase activity can suppress viral replication. Using in silico approaches, we have identified drugs that interact with SARS-CoV-2 helicase based on the presence of amino acid arrangements matching binding sites of drugs in previously annotated protein structures. The drugs exhibiting an RMSD of\u2009\u2264\u20093.0\u00a0\u00c5 were further analyzed using molecular docking, molecular dynamics (MD) simulation, and post-MD analyses. Using these approaches, we found 12 drugs that showed strong interactions with SARS-CoV-2 helicase amino acids. The analyses were performed using the recently available SARS-CoV-2 helicase structure (PDB ID: 5RL6). Based on the MM-GBSA approach, out of the 12 drugs, two drugs, namely posaconazole and grazoprevir, showed the most favorable binding energy, \u2212\u200954.8 and \u2212\u200949.1\u00a0kcal\/mol, respectively. Furthermore, of the amino acids found conserved among all human coronaviruses, 10\/11 and 10\/12 were targeted by, respectively, grazoprevir and posaconazole. These residues are part of the crucial DEAD-like helicase C and DEXXQc_Upf1-like\/ DEAD-like helicase domains. Strong interactions of posaconazole and grazoprevir with conserved amino acids indicate that the drugs can be potent against SARS-CoV-2. Since the amino acids are conserved among the human coronaviruses, the virus is unlikely to develop resistance mutations against these drugs. Since these drugs are already in use, they may be immediately repurposed for SARS-CoV-2 therapy.<\/jats:p>","DOI":"10.1038\/s41598-021-89724-0","type":"journal-article","created":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T10:04:23Z","timestamp":1620900263000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Repurposing potential of posaconazole and grazoprevir as inhibitors of SARS-CoV-2 helicase"],"prefix":"10.1038","volume":"11","author":[{"given":"Syed Hani","family":"Abidi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nahlah Makki","family":"Almansour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daulet","family":"Amerzhanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled S.","family":"Allemailem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wardah","family":"Rafaqat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud A. A.","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"la Fleur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Lukac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,13]]},"reference":[{"issue":"5","key":"89724_CR1","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S2213-2600(20)30079-5","volume":"8","author":"X Yang","year":"2020","unstructured":"Yang, X. et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir. Med. 8(5), 475\u2013481. https:\/\/doi.org\/10.1016\/S2213-2600(20)30079-5 (2020).","journal-title":"Lancet Respir. Med."},{"issue":"7","key":"89724_CR2","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1111\/all.14238","volume":"75","author":"JJ Zhang","year":"2020","unstructured":"Zhang, J. J. et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy 75(7), 1730\u20131741. https:\/\/doi.org\/10.1111\/all.14238 (2020).","journal-title":"Allergy"},{"issue":"18","key":"89724_CR3","doi-asserted-by":"publisher","first-page":"4085","DOI":"10.1111\/febs.12936","volume":"281","author":"R Hilgenfeld","year":"2014","unstructured":"Hilgenfeld, R. From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design. FEBS J. 281(18), 4085\u20134096 (2014).","journal-title":"FEBS J."},{"issue":"10224","key":"89724_CR4","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","volume":"395","author":"R Lu","year":"2020","unstructured":"Lu, R. et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 395(10224), 565\u2013574 (2020).","journal-title":"Lancet"},{"issue":"1","key":"89724_CR5","doi-asserted-by":"publisher","first-page":"56","DOI":"10.4103\/ijp.IJP_115_20","volume":"52","author":"M Prajapat","year":"2020","unstructured":"Prajapat, M. et al. Drug targets for corona virus: a systematic review. Indian J. Pharmacol. 52(1), 56\u201365 (2020).","journal-title":"Indian J. Pharmacol."},{"issue":"3","key":"89724_CR6","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.chom.2020.02.001","volume":"27","author":"A Wu","year":"2020","unstructured":"Wu, A. et al. Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China. Cell Host Microbe 27(3), 325\u2013328 (2020).","journal-title":"Cell Host Microbe"},{"issue":"6","key":"89724_CR7","first-page":"399","volume":"9","author":"KS Chan","year":"2003","unstructured":"Chan, K. S. et al. Treatment of severe acute respiratory syndrome with lopinavir\/ritonavir: a multicentre retrospective matched cohort study. Hong Kong Med. J. 9(6), 399\u2013406 (2003).","journal-title":"Hong Kong Med. J."},{"issue":"3","key":"89724_CR8","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1136\/thorax.2003.012658","volume":"59","author":"CM Chu","year":"2004","unstructured":"Chu, C. M. et al. Role of lopinavir\/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax 59(3), 252\u2013256 (2004).","journal-title":"Thorax"},{"key":"89724_CR9","doi-asserted-by":"crossref","unstructured":"Deng, L. et al. Arbidol combined with LPV\/r versus LPV\/r alone against Corona Virus Disease 2019: a retrospective cohort study. J. Infect. (2020).","DOI":"10.1016\/j.jinf.2020.03.002"},{"issue":"20","key":"89724_CR10","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa030634","volume":"348","author":"SM Poutanen","year":"2003","unstructured":"Poutanen, S. M. et al. Identification of severe acute respiratory syndrome in Canada. N. Engl. J. Med. 348(20), 1995\u20132005 (2003).","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"89724_CR11","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","volume":"30","author":"M Wang","year":"2020","unstructured":"Wang, M. et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 30(3), 269\u2013271 (2020).","journal-title":"Cell Res."},{"issue":"11","key":"89724_CR12","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.2174\/138161206776361147","volume":"12","author":"DN Frick","year":"2006","unstructured":"Frick, D. N. & Lam, A. M. Understanding helicases as a means of virus control. Curr. Pharm. Des. 12(11), 1315\u20131338 (2006).","journal-title":"Curr. Pharm. Des."},{"issue":"1","key":"89724_CR13","doi-asserted-by":"publisher","first-page":"4481","DOI":"10.1038\/s41598-020-61432-1","volume":"10","author":"KJ Jang","year":"2020","unstructured":"Jang, K. J. et al. A high ATP concentration enhances the cooperative translocation of the SARS coronavirus helicase nsP13 in the unwinding of duplex RNA. Sci. Rep. 10(1), 4481 (2020).","journal-title":"Sci. Rep."},{"key":"89724_CR14","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1146\/annurev.biochem.69.1.651","volume":"69","author":"SS Patel","year":"2000","unstructured":"Patel, S. S. & Picha, K. M. Structure and function of hexameric helicases. Annu. Rev. Biochem. 69, 651\u2013697 (2000).","journal-title":"Annu. Rev. Biochem."},{"key":"89724_CR15","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1146\/annurev.biochem.76.052305.115300","volume":"76","author":"MR Singleton","year":"2007","unstructured":"Singleton, M. R., Dillingham, M. S. & Wigley, D. B. Structure and mechanism of helicases and nucleic acid translocases. Annu. Rev. Biochem. 76, 23\u201350 (2007).","journal-title":"Annu. Rev. Biochem."},{"issue":"7","key":"89724_CR16","doi-asserted-by":"publisher","first-page":"3595","DOI":"10.1128\/JVI.02130-09","volume":"84","author":"YA Karpe","year":"2010","unstructured":"Karpe, Y. A. & Lole, K. S. NTPase and 5\u2019 to 3\u2019 RNA duplex-unwinding activities of the hepatitis E virus helicase domain. J. Virol. 84(7), 3595\u20133602 (2010).","journal-title":"J. Virol."},{"issue":"6","key":"89724_CR17","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1128\/AAC.46.6.1766-1772.2002","volume":"46","author":"UA Betz","year":"2002","unstructured":"Betz, U. A., Fischer, R., Kleymann, G., Hendrix, M. & Rubsamen-Waigmann, H. Potent in vivo antiviral activity of the herpes simplex virus primase-helicase inhibitor BAY 57\u20131293. Antimicrob. Agents Chemother. 46(6), 1766\u20131772 (2002).","journal-title":"Antimicrob. Agents Chemother."},{"issue":"10","key":"89724_CR18","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/nrd1853","volume":"4","author":"AD Kwong","year":"2005","unstructured":"Kwong, A. D., Rao, B. G. & Jeang, K. T. Viral and cellular RNA helicases as antiviral targets. Nat. Rev. Drug Discov. 4(10), 845\u2013853 (2005).","journal-title":"Nat. Rev. Drug Discov."},{"issue":"4","key":"89724_CR19","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/nm0402-386","volume":"8","author":"JJ Crute","year":"2002","unstructured":"Crute, J. J. et al. Herpes simplex virus helicase-primase inhibitors are active in animal models of human disease. Nat. Med. 8(4), 386\u2013391 (2002).","journal-title":"Nat. Med."},{"issue":"3","key":"89724_CR20","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.chembiol.2005.01.006","volume":"12","author":"JA Tanner","year":"2005","unstructured":"Tanner, J. A. et al. The adamantane-derived bananins are potent inhibitors of the helicase activities and replication of SARS coronavirus. Chem. Biol. 12(3), 303\u2013311 (2005).","journal-title":"Chem. Biol."},{"issue":"7","key":"89724_CR21","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.arcmed.2020.05.024","volume":"51","author":"S Habtemariam","year":"2020","unstructured":"Habtemariam, S. et al. Should we try SARS-CoV-2 helicase inhibitors for COVID-19 therapy? Arch. Med. Res. 51(7), 733\u2013735. https:\/\/doi.org\/10.1016\/j.arcmed.2020.05.024 (2020).","journal-title":"Arch. Med. Res."},{"issue":"9","key":"89724_CR22","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1097\/CM9.0000000000000797","volume":"133","author":"HH Fan","year":"2020","unstructured":"Fan, H. H. et al. Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus (2019-nCoV) related coronavirus model. Chin. Med. J. (Engl) 133(9), 1051\u20131056. https:\/\/doi.org\/10.1097\/CM9.0000000000000797 (2020).","journal-title":"Chin. Med. J. (Engl)"},{"issue":"10","key":"89724_CR23","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1101\/gr.278202","volume":"12","author":"LY Geer","year":"2002","unstructured":"Geer, L. Y., Domrachev, M., Lipman, D. J. & Bryant, S. H. CDART: protein homology by domain architecture. Genome Res. 12(10), 1619\u20131623 (2002).","journal-title":"Genome Res."},{"issue":"D1","key":"89724_CR24","doi-asserted-by":"publisher","first-page":"D265","DOI":"10.1093\/nar\/gkz991","volume":"48","author":"S Lu","year":"2020","unstructured":"Lu, S. et al. CDD\/SPARCLE: the conserved domain database in 2020. Nucleic Acids Res. 48(D1), D265\u2013D268 (2020).","journal-title":"Nucleic Acids Res."},{"issue":"5016","key":"89724_CR25","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1126\/science.1853201","volume":"253","author":"JU Bowie","year":"1991","unstructured":"Bowie, J. U., Luthy, R. & Eisenberg, D. A method to identify protein sequences that fold into a known three-dimensional structure. Science 253(5016), 164\u2013170 (1991).","journal-title":"Science"},{"key":"89724_CR26","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/S0076-6879(97)77022-8","volume":"277","author":"D Eisenberg","year":"1997","unstructured":"Eisenberg, D., Luthy, R. & Bowie, J. U. VERIFY3D: assessment of protein models with three-dimensional profiles. Methods Enzymol. 277, 396\u2013404 (1997).","journal-title":"Methods Enzymol."},{"issue":"6364","key":"89724_CR27","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/356083a0","volume":"356","author":"R Luthy","year":"1992","unstructured":"Luthy, R., Bowie, J. U. & Eisenberg, D. Assessment of protein models with three-dimensional profiles. Nature 356(6364), 83\u201385 (1992).","journal-title":"Nature"},{"issue":"W1","key":"89724_CR28","doi-asserted-by":"publisher","first-page":"W350","DOI":"10.1093\/nar\/gkz391","volume":"47","author":"NS Ab Ghani","year":"2019","unstructured":"Ab Ghani, N. S., Ramlan, E. I. & Firdaus-Raih, M. Drug ReposER: a web server for predicting similar amino acid arrangements to known drug binding interfaces for potential drug repositioning. Nucleic Acids Res. 47(W1), W350\u2013W356 (2019).","journal-title":"Nucleic Acids Res."},{"key":"89724_CR29","unstructured":"SZYBKI 1.9.0.3. 1.9.0.3 ed. Santa Fe, NM, USA: OpenEye Scientific Software; 2016."},{"issue":"7","key":"89724_CR30","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1002\/(SICI)1096-987X(199905)20:7<720::AID-JCC7>3.0.CO;2-X","volume":"20","author":"TAMMFFVI Halgren","year":"1999","unstructured":"Halgren, T. A. M. M. F. F. V. I. MMFF94s option for energy minimization studies. J. Comput. Chem. 20(7), 720\u2013729 (1999).","journal-title":"J. Comput. Chem."},{"key":"89724_CR31","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1758-2946-3-33","volume":"3","author":"NM O'Boyle","year":"2011","unstructured":"O\u2019Boyle, N. M. et al. Open babel: an open chemical toolbox. J. Cheminform. 3, 33 (2011).","journal-title":"J. Cheminform."},{"key":"89724_CR32","doi-asserted-by":"publisher","first-page":"W368","DOI":"10.1093\/nar\/gki464","volume":"33","author":"JC Gordon","year":"2005","unstructured":"Gordon, J. C. et al. H++: a server for estimating pKas and adding missing hydrogens to macromolecules. Nucleic Acids Res. 33, W368\u2013W371 (2005).","journal-title":"Nucleic Acids Res."},{"issue":"5","key":"89724_CR33","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1038\/nprot.2016.051","volume":"11","author":"S Forli","year":"2016","unstructured":"Forli, S. et al. Computational protein-ligand docking and virtual drug screening with the AutoDock suite. Nat. Protoc. 11(5), 905\u2013919 (2016).","journal-title":"Nat. Protoc."},{"issue":"16","key":"89724_CR34","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1002\/jcc.21256","volume":"30","author":"GM Morris","year":"2009","unstructured":"Morris, G. M. et al. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J. Comput. Chem. 30(16), 2785\u20132791 (2009).","journal-title":"J. Comput. Chem."},{"issue":"2","key":"89724_CR35","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","volume":"31","author":"O Trott","year":"2010","unstructured":"Trott, O. & Olson, A. J. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 31(2), 455\u2013461 (2010).","journal-title":"J. Comput. Chem."},{"key":"89724_CR36","volume-title":"AMBER 2016","author":"DA Case","year":"2016","unstructured":"Case, D. A. et al. AMBER 2016 (University of California, 2016)."},{"issue":"9","key":"89724_CR37","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1002\/jcc.20035","volume":"25","author":"J Wang","year":"2004","unstructured":"Wang, J., Wolf, R. M., Caldwell, J. W., Kollman, P. A. & Case, D. A. Development and testing of a general amber force field. J. Comput. Chem. 25(9), 1157\u20131174 (2004).","journal-title":"J. Comput. Chem."},{"issue":"8","key":"89724_CR38","doi-asserted-by":"publisher","first-page":"3696","DOI":"10.1021\/acs.jctc.5b00255","volume":"11","author":"JA Maier","year":"2015","unstructured":"Maier, J. A. et al. ff14SB: improving the accuracy of protein side chain and backbone parameters from ff99SB. J. Chem. Theory Comput. 11(8), 3696\u20133713 (2015).","journal-title":"J. Chem. Theory Comput."},{"issue":"40","key":"89724_CR39","doi-asserted-by":"publisher","first-page":"10269","DOI":"10.1021\/j100142a004","volume":"97","author":"CI Bayly","year":"1993","unstructured":"Bayly, C. I., Cieplak, P., Cornell, W. & Kollman, P. A. A well-behaved electrostatic potential based method using charge restraints for deriving atomic charges: the RESP model. J. Phys. Chem. 97(40), 10269\u201310280 (1993).","journal-title":"J. Phys. Chem."},{"key":"89724_CR40","unstructured":"Frisch, M. J. et al. Gaussian 09. Revision E01 ed. (Gaussian Inc., 2009)."},{"issue":"12","key":"89724_CR41","doi-asserted-by":"publisher","first-page":"10089","DOI":"10.1063\/1.464397","volume":"98","author":"T Darden","year":"1993","unstructured":"Darden, T., York, D. & Pedersen, L. Particle mesh Ewald: an N\u22c5log(N) method for Ewald sums in large systems. J. Chem. Phys. 98(12), 10089\u201310092 (1993).","journal-title":"J. Chem. Phys."},{"issue":"8","key":"89724_CR42","doi-asserted-by":"publisher","first-page":"3684","DOI":"10.1063\/1.448118","volume":"81","author":"HJC Berendsen","year":"1984","unstructured":"Berendsen, H. J. C., Postma, J. P. M., Gunsteren, W. F. V., DiNola, A. & Haak, J. R. Molecular dynamics with coupling to an external bath. J. Chem. Phys. 81(8), 3684\u20133690 (1984).","journal-title":"J. Chem. Phys."},{"issue":"1","key":"89724_CR43","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1023\/A:1008763014207","volume":"18","author":"I Massova","year":"2000","unstructured":"Massova, I. & Kollman, P. A. Combined molecular mechanical and continuum solvent approach (MM-PBSA\/GBSA) to predict ligand binding. Perspect. Drug Discov. Des. 18(1), 113\u2013135 (2000).","journal-title":"Perspect. Drug Discov. Des."},{"issue":"1","key":"89724_CR44","doi-asserted-by":"publisher","first-page":"20885","DOI":"10.1038\/s41598-020-77720-9","volume":"10","author":"R Khalid","year":"2020","unstructured":"Khalid, R. et al. An in silico approach to analyze HCV genotype-specific binding-site variation and its effect on drug-protein interaction. Sci Rep. 10(1), 20885 (2020).","journal-title":"Sci Rep."},{"issue":"Web Server issu","key":"89724_CR45","doi-asserted-by":"publisher","first-page":"W320","DOI":"10.1093\/nar\/gku316","volume":"42","author":"X Robert","year":"2014","unstructured":"Robert, X. & Gouet, P. Deciphering key features in protein structures with the new ENDscript server. Nucleic Acids Res. 42(Web Server issue), W320\u2013W324 (2014).","journal-title":"Nucleic Acids Res."},{"key":"89724_CR46","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.compbiolchem.2016.08.007","volume":"64","author":"Y Ding","year":"2016","unstructured":"Ding, Y. et al. Assessing the similarity of ligand binding conformations with the Contact Mode Score. Comput. Biol. Chem. 64, 403\u2013413 (2016).","journal-title":"Comput. Biol. Chem."},{"issue":"1","key":"89724_CR47","doi-asserted-by":"publisher","first-page":"3752","DOI":"10.1038\/s41467-018-06313-y","volume":"9","author":"J Kanaan","year":"2018","unstructured":"Kanaan, J. et al. UPF1-like helicase grip on nucleic acids dictates processivity. Nat. Commun. 9(1), 3752 (2018).","journal-title":"Nat. Commun."},{"issue":"1","key":"89724_CR48","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0959-440X(02)00298-1","volume":"12","author":"JM Caruthers","year":"2002","unstructured":"Caruthers, J. M. & McKay, D. B. Helicase structure and mechanism. Curr. Opin. Struct. Biol. 12(1), 123\u2013133 (2002).","journal-title":"Curr. Opin. Struct. Biol."},{"issue":"3","key":"89724_CR49","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S0959-440X(05)80116-2","volume":"3","author":"A Gorbalenya","year":"1993","unstructured":"Gorbalenya, A. & Koonin, E. Helicases: amino acid sequence comparisons and structure-function relationships. Curr. Opin. Struct. Biol. 3(3), 319\u2013429 (1993).","journal-title":"Curr. Opin. Struct. Biol."},{"issue":"7","key":"89724_CR50","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0092-8674(02)00804-8","volume":"109","author":"JR Lorsch","year":"2002","unstructured":"Lorsch, J. R. RNA chaperones exist and DEAD box proteins get a life. Cell 109(7), 797\u2013800 (2002).","journal-title":"Cell"},{"issue":"19","key":"89724_CR51","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1101\/gad.11.19.2545","volume":"11","author":"MM Kessler","year":"1997","unstructured":"Kessler, M. M. et al. Hrp1, a sequence-specific RNA-binding protein that shuttles between the nucleus and the cytoplasm, is required for mRNA 3\u2019-end formation in yeast. Genes Dev. 11(19), 2545\u20132556 (1997).","journal-title":"Genes Dev."},{"issue":"5","key":"89724_CR52","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1017\/S1355838298980190","volume":"4","author":"MC Daugeron","year":"1998","unstructured":"Daugeron, M. C. & Linder, P. Dbp7p, a putative ATP-dependent RNA helicase from Saccharomyces cerevisiae, is required for 60S ribosomal subunit assembly. RNA 4(5), 566\u2013581 (1998).","journal-title":"RNA"},{"issue":"Database issue","key":"89724_CR53","doi-asserted-by":"publisher","first-page":"D901","DOI":"10.1093\/nar\/gkm958","volume":"36","author":"DS Wishart","year":"2008","unstructured":"Wishart, D. S. et al. DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 36(Database issue), D901\u2013D906 (2008).","journal-title":"Nucleic Acids Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-89724-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-89724-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-89724-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T17:58:24Z","timestamp":1699034304000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-89724-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,13]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["89724"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-89724-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,13]]},"assertion":[{"value":"11 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10290"}}